Immunology biotech Agomab Therapeutics is seeking to raise up to $212.5 million in its Nasdaq debut, joining a series of biotechs chipping away at 2025’s iced-over IPO market. | Immunology biotech ...

Immunology biotech Agomab Therapeutics and eye-focused SpyGlass Pharma have both unveiled their intentions to go public, in ...

Amid a rebound in SPAC activity, the prolific “crossover” investor is aiming for its third blank-check merger since 2022 ...

Two more biopharma companies—the hair-growth specialist Veradermics and cancer-focused Eikon Therapeutics—have announced ...

The South San Francisco start-up is offering 17.6 million shares at a price range of $16 to $18, which would give the company ...

The BIM-IOL is designed to be implanted during cataract surgery, tackling IOP while restoring vision, and SpyGlass is also ...

Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments.

Run by Roger Perlmutter and backed by more than $1 billion in private funding, Eikon will use the IPO proceeds to advance a ...

By Sriparna Roy and Christy Santhosh Jan 14 (Reuters) - Investors are eyeing a rebound in the U.S. biotech sector in 2026, as more companies are expected to go public amid a renewed deal-making ...

Belgian biotech Agomab Therapeutics has set the terms for its planned US initial public offering, according to a filing with ...

As global capital markets recalibrate, Hong Kong is re-emerging in 2026 as a strategic listing venue of first choice, rather ...

Delve into what 2026 has to offer in the biotech industry. The market is showing signs it's picking up and the patent cliff ...